Cargando…
Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera
A high percentage of patients with the myeloproliferative disorder polycythemia vera (PV) harbor a Val617→Phe activating mutation in the Janus kinase 2 (JAK2) gene, and both cell culture and mouse models have established a functional role for this mutation in the development of this disease. We desc...
Autores principales: | Kraus, Manfred, Wang, Yuxun, Aleksandrowicz, Dan, Bachman, Eric, Szewczak, Alexander A., Walker, Deborah, Xu, Lin, Bouthillette, Melaney, Childers, Kaleen M., Dolinski, Brian, Haidle, Andrew M., Kopinja, Johnny, Lee, Linda, Lim, Jongwon, Little, Kevin D., Ma, Yanhong, Mathur, Anjili, Mo, Jan-Rung, O’Hare, Erin, Otte, Ryan D., Taoka, Brandon M., Wang, Wenxian, Yin, Hong, Zabierek, Anna A., Zhang, Weisheng, Zhao, Shuxia, Zhu, Joe, Young, Jonathan R., Marshall, C. Gary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356383/ https://www.ncbi.nlm.nih.gov/pubmed/22623993 http://dx.doi.org/10.1371/journal.pone.0037207 |
Ejemplares similares
-
Splenectomy Normalizes Hematocrit in Murine Polycythemia Vera
por: Mo, Jan-Rung, et al.
Publicado: (2009) -
Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016) -
Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019) -
Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022) -
Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)